PURPOSE: Since primary tumor cells from patients have been used as a model for assessment of drug response for individual patients, this study aims to evaluate the reliability of such a model in colorectal cancer (CRC) in predicting the response of tumor tissues through comparison of their expression profiles. METHODS: Establishment of primary cultures from tissues obtained surgically from CRC patients allowed us to study the gene expression differences between normal and tumor tissues as well as primary cultures derived from the tumor mass. The tissues comparison highlights the molecular characteristics of tumors, while the comparison between primary tumor cells versus normal and tumor tissues allowed us to identify alterations associated with the establishment of culture. Genes-drug association analyses allowed us to fine-tune our expectations while using primary culture as a model for drug assessment. RESULTS: Comparison between tumor cultures and original tissues through functional analyses showed the deregulations caused by culture establishment. Investigating the impact of such changes in genes-drug associations to identify the potential alterations in drug response, we found that primary cultures may have increased susceptibility toward paclitaxel, but reduced susceptibility toward analogues of fluorouracil compared with original tumors. CONCLUSIONS: Response of primary tumor cells toward different drugs is not linearly associated to tumor tissues. Our results highlight the importance to account for the discrepancy in responses between the primary tumor cells and original counterparts in order to provide clinicians with important insights to improve selection of drugs for individual patients based on in vitro assays.
PURPOSE: Since primary tumor cells from patients have been used as a model for assessment of drug response for individual patients, this study aims to evaluate the reliability of such a model in colorectal cancer (CRC) in predicting the response of tumor tissues through comparison of their expression profiles. METHODS: Establishment of primary cultures from tissues obtained surgically from CRCpatients allowed us to study the gene expression differences between normal and tumor tissues as well as primary cultures derived from the tumor mass. The tissues comparison highlights the molecular characteristics of tumors, while the comparison between primary tumor cells versus normal and tumor tissues allowed us to identify alterations associated with the establishment of culture. Genes-drug association analyses allowed us to fine-tune our expectations while using primary culture as a model for drug assessment. RESULTS: Comparison between tumor cultures and original tissues through functional analyses showed the deregulations caused by culture establishment. Investigating the impact of such changes in genes-drug associations to identify the potential alterations in drug response, we found that primary cultures may have increased susceptibility toward paclitaxel, but reduced susceptibility toward analogues of fluorouracil compared with original tumors. CONCLUSIONS: Response of primary tumor cells toward different drugs is not linearly associated to tumor tissues. Our results highlight the importance to account for the discrepancy in responses between the primary tumor cells and original counterparts in order to provide clinicians with important insights to improve selection of drugs for individual patients based on in vitro assays.
Authors: Augusta Fernando; Sharon Glaysher; Mark Conroy; Marcin Pekalski; Jason Smith; Louise A Knight; Federica Di Nicolantonio; Ian A Cree Journal: Anticancer Drugs Date: 2006-09 Impact factor: 2.248
Authors: Rossanna C Pezo; Saumil J Gandhi; L Andrew Shirley; Richard G Pestell; Leonard H Augenlicht; Robert H Singer Journal: Cancer Res Date: 2008-07-01 Impact factor: 12.701
Authors: Steven Eschrich; Ivana Yang; Greg Bloom; Ka Yin Kwong; David Boulware; Alan Cantor; Domenico Coppola; Mogens Kruhøffer; Lauri Aaltonen; Torben F Orntoft; John Quackenbush; Timothy J Yeatman Journal: J Clin Oncol Date: 2005-05-20 Impact factor: 44.544
Authors: M Miyaki; M Seki; M Okamoto; A Yamanaka; Y Maeda; K Tanaka; R Kikuchi; T Iwama; T Ikeuchi; A Tonomura Journal: Cancer Res Date: 1990-11-15 Impact factor: 12.701
Authors: Shaowu Tang; Ying Ding; Etienne Sibille; Jeffrey Mogil; William R Lariviere; George C Tseng Journal: Ann Appl Stat Date: 2014-12 Impact factor: 2.083